15763 Results

People

  1. Hudis
    Hudis
  2. Offit
    Offit
  3. Zelefsky
    Zelefsky
  4. Giralt
    Giralt
  5. Robson
    Robson
  6. Yahalom
    Yahalom
  7. Wolden
    Wolden
  8. Coit
    Coit
  9. Marghoob
    Marghoob
  10. Tuttle
    Tuttle

Groups

  1. Survivorship Research (15763)
  2. Department of Medicine (9202)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5184)
  5. Surgery (5131)
  6. Epidemiology and Biostatistics (3598)
  7. Division of Subspecialty Medicine (3242)
  8. Center for Hematologic Malignancies (2610)
  9. Biostatistics Service (2488)
  10. GSK Faculty (2413)
  1. "Survivorship Research"
Formats
  1. Journal Article (8900)
  2. Meeting Abstract (5192)
  3. Book Section (571)
  4. Review (357)
  5. Editorial (225)
  6. Research Letter (132)
  7. Conference Paper (104)
  8. Correspondence (91)
  9. Guidelines (85)
  10. Miscellaneous (76)
  11. Book Whole (30)
Groups
  1. Survivorship Research (15763)
  2. Department of Medicine (9202)
  3. Population Sciences Research Program (5670)
  4. Solid Tumor Oncology Division (5184)
  5. Surgery (5131)
  6. Epidemiology and Biostatistics (3598)

More Groups

People
  1. Clifford Hudis (905)
  2. Kenneth Offit (788)
  3. Michael Zelefsky (754)
  4. Sergio Giralt (684)
  5. Mark Robson (676)
  6. Joachim Yahalom (625)

More People

Years
  1. 2025 (231)
  2. 2024 (802)
  3. 2023 (892)
  4. 2022 (906)
  5. 2021 (922)
  6. 2020 (930)

More Years

Publications
  1. Journal of Clinical Oncology (1873)
  2. International Journal of Radiation Oncology, Biology, Physics (908)
  3. Blood (685)
  4. Annals of Surgical Oncology (599)
  5. Cancer Research (333)
  6. Cancer (331)

More Publications

Publishers
  1. Elsevier Inc. (2658)
  2. American Society of Clinical Oncology (2019)
  3. Springer (1542)
  4. Wiley Blackwell (806)
  5. Oxford University Press (787)
  6. American Society of Hematology (748)

More Publishers

Results (15763)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose-adjusted EPOCH plus /- rituximab in older patients with high grade diffuse large B-cell lymphoma, Burkitt and T-cell lymphoma: An effective regimen with acceptable toxicity profile
    Meeting Abstract

    Owens, C. N.; Migliacci, J. C.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Younes, A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Efficacy and risk factors analysis of upfront autologous stem cell mobilization using plerixafor and granulocyte-colony stimulating factor (GCSF) in patients with multiple myeloma
    Meeting Abstract

    Ogunniyi, A.; Rodriguez, M.; Devlin, S. M.; Adel, N. G.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A. M.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Extended use of rituximab in older adults with non-Hodgkin lymphoma
    Meeting Abstract

    Matasar, M. J.; Atoria, C. L.; Elkin, E. B.; Nabhan, C.
    Blood (2014)

    Fulltext@MSK | Save
  • Phase 2 study of bendamustine in combination with dexamethasone (Ben/Dex) in patients with previously-treated systemic light chain (AL) amyloidosis
    Meeting Abstract

    Lentzsch, S.; Comenzo, R. L.; Osman, K.; Zikaras, K.; Backenroth, D.; Tsai, W. Y.; Sanchorawala, V.; Landau, H.
    Blood (2014)

    Fulltext@MSK | Save
  • Increased bone marrow plasma cells at diagnosis predicts overall mortality in AL amyloidosis patients undergoing risk-adapted stem cell transplant
    Meeting Abstract

    Landry, C. A.; Smith, M.; Chou, J. F.; Devlin, S. M.; Hassoun, H.; Bello, C.; Landgren, O.; Giralt, S.; Comenzo, R. L.; Landau, H.
    Blood (2014)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma: Final results from the NCI phase 2 pilot study
    Meeting Abstract

    Landgren, O.; Roschewski, M.; Mailankody, S.; Kwok, M.; Manasanch, E. E.; Bhutani, M.; Tageja, N.; Kazandjian, D.; Zingone, A.; Costello, R.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD) testing in newly diagnosed multiple myeloma (MM) patients: A prospective head-to-head assessment of cell-based, molecular, and molecular-imaging modalities
    Meeting Abstract

    Korde, N.; Mailankody, S.; Roschewski, M.; Faham, M.; Kotwaliwale, C.; Moorhead, M.; Kwok, M. L.; Manasanch, E. E.; Bhutani, M.; Tageja, N.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Series of hairy cell leukemia patients with co-existent plasma cell disorders
    Meeting Abstract

    Korde, N.; Mailankody, S.; Arons, E.; Braylan, R. C.; Raffeld, M.; Maestri, E.; Yuan, C.; Stetler-Stevenson, M.; Landgren, O.; Maric, I.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Biomarker proteasome levels predict response to combination therapy with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Korde, N.; Dosani, T.; Simakova, O.; Mailankody, S.; Costello, R.; Roschewski, M.; Yuan, C.; Stetler-Stevenson, M.; Figg, W. D.; Landgren, O.; more...
    Blood (2014)

    Fulltext@MSK | Save